Genmab A/S (GMAB) Q3 2023 Earnings Conference Call November 7, 2023 12:00 PM ET

Company Participants

Jan van de Winkel - Co-Founder, President & Chief Executive Officer

Anthony Pagano - Executive Vice President & Chief Financial Officer

Judith Klimovsky - Chief Development Officer

Anthony Mancini - Chief Operating Officer

Tahi Ahmadi - Chief Medical Officer

Conference Call Participants

Vikram Purohit - Morgan Stanley

Jonathan Chang - Leerink

Paul Jeng - Guggenheim Partners

Etzer Darout - BMO

Sachin Jain - Bank of America

Kaveri Pohlman - BTIG

Michael Novod - Nordea

Emily Field - Barclays

Operator

Hello, and welcome to Genmab's Third Quarter 2023 Financial Results Conference Call. As a reminder, this conference call is being recorded.

During this telephone conference, you may be presented with forward-looking statements that include words such as believes, anticipates, plans, or expects. Actual results may differ materially, for example, as a result of delays or and successful development projects. Genmab is not under any obligation to update statements regarding the future nor to confirm such statements in relation to actual results unless this is required by law.

Please also note that Genmab may hold your personal data as indicated by you as part of our Investor Relations outreach activities in order to update you on Genmab going. Please refer to our website for more information on Genmab and our privacy policy.

I would now like to hand the conference over to your first speaker today, Jan van de Winkel. Please go ahead.

Jan van de Winkel

Hello, and welcome to Genmab's conference call to discuss our financial results for the period ending September 30, 2023. With me today to present these results is our CFO, Anthony Pagano. For the Q&A, we will be joined by our Chief Development Officer, Judith Klimovsky; our Chief Operating Officer, Anthony Mancini and our Chief Medical Officer, Tahi Ahmadi.

As already said, we will be making forward-looking statements, so please keep that in mind as we go through this call. During today's presentation, we will reference products being developed under some of our strategic collaborations. This slide acknowledges those relationships.

Genmab's strong foundation is built on our consistent track record of success. As we near the end of the year, it's a good time to reflect on how far we have come as a company even in the last 12 months. We continue to expand our pipeline with new INDs and new product candidates in the clinic. We also matured our pipeline with new clinical trials and positive data readouts. And very excitingly, there are now eight approved medicines that are followed by our innovations, half of which were created with our proprietary DuoBody technology.